Amiloride Enhances Prostate Cancer Cell Sensitivity to Lapatinib
Author Information
Author(s): Jathal Maitreyee K., Mudryj Maria, Dall’Era Marc A., Ghosh Paramita M.
Primary Institution: University of California Davis
Hypothesis
Can amiloride enhance the effectiveness of lapatinib in treating hormone-sensitive prostate cancer cells?
Conclusion
The combination of amiloride and lapatinib significantly increases apoptosis in hormone-sensitive prostate cancer cells without affecting androgen receptor activity.
Supporting Evidence
- Amiloride promoted ErbB3 translocation from the nucleus to the cytoplasm.
- Combination treatment significantly increased apoptosis in hormone-sensitive prostate cancer cells.
- Lapatinib alone was ineffective in inhibiting prostate cancer cell growth.
Takeaway
This study shows that a common diuretic called amiloride can help make prostate cancer cells more sensitive to a cancer drug called lapatinib, which could improve treatment outcomes.
Methodology
The study involved treating prostate cancer cell lines with amiloride and lapatinib, followed by various assays to measure cell viability and apoptosis.
Potential Biases
Potential bias in the selection of cell lines and treatment concentrations used.
Limitations
The study primarily focused on in vitro models, which may not fully replicate in vivo conditions.
Participant Demographics
The study used human prostate cancer cell lines, including LNCaP, C4-2, and 22Rv1.
Statistical Information
P-Value
p=0.0236
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website